{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:34:06Z","timestamp":1757590446509},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T00:00:00Z","timestamp":1472083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"DOI":"10.1371\/journal.pcbi.1005077","type":"journal-article","created":{"date-parts":[[2016,8,25]],"date-time":"2016-08-25T17:43:08Z","timestamp":1472146988000},"page":"e1005077","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors"],"prefix":"10.1371","volume":"12","author":[{"given":"Danika","family":"Lindsay","sequence":"first","affiliation":[]},{"given":"Colleen M.","family":"Garvey","sequence":"additional","affiliation":[]},{"given":"Shannon M.","family":"Mumenthaler","sequence":"additional","affiliation":[]},{"given":"Jasmine","family":"Foo","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2016,8,25]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ctrv.2010.05.001","article-title":"The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents","volume":"37","author":"DW Siemann","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 4","key":"ref2","first-page":"19","article-title":"The impact of microenvironmental heterogeneity on the evolution of drug resistance in cancer cells","volume":"14","author":"SM Mumenthaler","year":"2015","journal-title":"Cancer Inform"},{"issue":"19","key":"ref3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"O Tredan","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"47","key":"ref4","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1038\/sj.onc.1206943","article-title":"Role of the tumor microenvironment in mediating <italic>de novo<\/italic> resistance to drugs and physiological mediators of cell death","volume":"22","author":"LA Hazlehurst","year":"2003","journal-title":"Oncogene"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001622-200011000-00008","article-title":"The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance","volume":"12","author":"KH Shain","year":"2000","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1054\/drup.1999.0097","article-title":"The tumor microenvironment as a determinant of drug response and resistance","volume":"2","author":"WS Dalton","year":"1999","journal-title":"Drug Resist Updat"},{"issue":"2","key":"ref7","first-page":"169","article-title":"Drug resistance mediated by cellular stress response to the microenvironment of solid tumors","volume":"14","author":"A Tomida","year":"1999","journal-title":"Anticancer Drug Des"},{"issue":"27","key":"ref8","doi-asserted-by":"crossref","first-page":"10775","DOI":"10.1073\/pnas.1117716109","article-title":"On the rapidity of antibiotic resistance evolution facilitated by a concentration gradient","volume":"109","author":"R Hermsen","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6050","key":"ref9","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1126\/science.1208747","article-title":"Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments","volume":"333","author":"Q Zhang","year":"2011","journal-title":"Science"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: definitions and current clinical, biological, and molecular aspects","volume":"93","author":"M Hockel","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"AI Minchinton","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/jcp.1041510220","article-title":"Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH","volume":"151","author":"JJ Casciari","year":"1992","journal-title":"J Cell Physiol"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/sj.bjc.6603922","article-title":"Cellular adaptations to hypoxia and acidoses during somatic evolution of breast cancer","volume":"97","author":"RA Gatenby","year":"2007","journal-title":"Br J Cancer"},{"issue":"13","key":"ref14","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.2014.60.0759","article-title":"Targeting tumor hypoxia with hypoxia-activated prodrugs","volume":"33","author":"JJ Yeh","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(00)00006-1","article-title":"The role of hypoxia-activated prodrugs in cancer therapy","volume":"1","author":"WA Denny","year":"2000","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/1078-0432.CCR-11-1980","article-title":"Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer","volume":"18","author":"JD Sun","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood-2010-02-269126","article-title":"Targeting the multiple myeloma hyoxic niche with TH-302, a hypoxia-activated prodrug","volume":"116","author":"J Hu","year":"2010","journal-title":"Blood"},{"key":"ref18","article-title":"Targeting the hypoxic fraction of tumors using hypoxia-activated prodrugs","author":"RM Phillips","year":"2016","journal-title":"Cancer Chemother Parmacol"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/1535-7163.MCT-11-0634","article-title":"Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302","volume":"11","author":"F Meng","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5732\/cjc.012.10285","article-title":"Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia","volume":"33","author":"CP Guise","year":"2014","journal-title":"Chin J Cancer"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1097\/JTO.0b013e31826146ee","article-title":"Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer","volume":"7","author":"J Foo","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"90","key":"ref22","doi-asserted-by":"crossref","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"J Chmielecki","year":"2011","journal-title":"Sci Transl Med"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1021\/mp200270v","article-title":"Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancer","volume":"8","author":"SM Mumenthaler","year":"2011","journal-title":"Mol Pharm"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","article-title":"Evolution of acquired resistance to anti-cancer therapy","volume":"355","author":"J Foo","year":"2014","journal-title":"Journal of theoretical biology"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"e4423","DOI":"10.1371\/journal.pone.0004423","article-title":"Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia","volume":"4","author":"NL Komarova","year":"2009","journal-title":"PLoS One"},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"e12300","DOI":"10.1371\/journal.pone.0012300","article-title":"Optimizing combination therapies with existing and future CML drugs","volume":"5","author":"AA Katouli","year":"2010","journal-title":"PloS one"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e00747","DOI":"10.7554\/eLife.00747","article-title":"Evolutionary dynamics of cancer in response to targeted combination therapy","volume":"2","author":"I Bozic","year":"2013","journal-title":"Elife"},{"issue":"36","key":"ref28","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"W Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1101\/sqb.2005.70.043","article-title":"Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors","volume":"70","author":"DA Haber","year":"2005","journal-title":"Cold Spring Harb Symp Quant Biol"},{"issue":"16","key":"ref30","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","article-title":"Determinants of tumor response and survival with erlotinib in patients with non-small cell lung cancer","volume":"22","author":"R Perez-Soler","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Med"},{"issue":"17","key":"ref32","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-07-0560","article-title":"Prospective assessment of discontinuation and reinitiation of erlotinib and gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus","volume":"13","author":"GJ Riely","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer","volume":"7","author":"AJ Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"suppl; abstr 7547","key":"ref34","article-title":"Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer","volume":"30","author":"GR Oxnard","year":"2012","journal-title":"J Clin Oncol"},{"issue":"13","key":"ref35","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1158\/0008-5472.CAN-11-3720","article-title":"Combined EGFR\/MET or EGFR\/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET","volume":"72","author":"L Xu","year":"2012","journal-title":"Cancer Res"},{"issue":"10","key":"ref36","first-page":"3000","article-title":"Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer","volume":"119","author":"L Regales","year":"2009","journal-title":"J Clin Invest"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1089\/ars.2007.1628","article-title":"Detection and characterization of tumor hypoxia using pO<sub>2<\/sub> histography","volume":"9","author":"P Vaupel","year":"2007","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/88859","article-title":"High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection","volume":"28","author":"HA Coller","year":"2001","journal-title":"Nat Genet"},{"issue":"18","key":"ref39","doi-asserted-by":"crossref","first-page":"8111","DOI":"10.1158\/0008-5472.CAN-04-1198","article-title":"A quantitative measurement of the human somatic mutation rate","volume":"65","author":"DJ Araten","year":"2005","journal-title":"Cancer Res"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jtbi.2009.11.022","article-title":"Evolution of resistance to anti-cancer therapy during general dosing schedules","volume":"263","author":"J Foo","year":"2010","journal-title":"J Theor Biol"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1215\/S1522851705000451","article-title":"Phase 1 study of erlotinib HCI alone and combined with temozolomide in patients with stable or recurrent malignant glioma","volume":"8","author":"MD Prados","year":"2006","journal-title":"Neuro Oncol"},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/bjc.2011.332","article-title":"Erlotinib\u2019dosing-to-rash\u2019: a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer","volume":"105","author":"AC Mita","year":"2011","journal-title":"Br J Cancer"},{"issue":"9","key":"ref43","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1158\/1078-0432.CCR-10-3425","article-title":"Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies","volume":"17","author":"GJ Weiss","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/ijc.28595","article-title":"Activity of the hypoxia-activated prodrug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy","volume":"134","author":"JK Saggar","year":"2014","journal-title":"Int J Cancer"},{"issue":"13","key":"ref45","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"M Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/cncr.22088","article-title":"A phase I\/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer","volume":"107","author":"DT Milton","year":"2006","journal-title":"Cancer"},{"issue":"21","key":"ref47","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1182\/blood.V122.21.3920.3920","article-title":"A phase 1 study of TH-302, an investigational hypoxia-targeted drug, in patients with advanced leukemias","volume":"122","author":"M Konopleva","year":"2013","journal-title":"Blood"},{"issue":"11","key":"ref48","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-1853","article-title":"Combined antitumor therapy with metronic topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma and rhabdomyosarcoma preclinical models","volume":"22","author":"L Zhang","year":"2016","journal-title":"Clin Cancer Res"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pcbi.1005077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T14:30:41Z","timestamp":1601044241000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1005077"}},"subtitle":[],"editor":[{"given":"Natalia L.","family":"Komarova","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2016,8,25]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1005077","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,25]]}}}